Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31707305 | 1.00 | MEN1 (0.42) | MEN1HTR2AHTR2CSIGMAR1PNMT | |
| SCHEMBL5708935 | 0.82 | CD274 (0.43) | MEN1HTR2AHTR2CPNMTCD44 | |
| SCHEMBL25267820 | 0.81 | SIGMAR1 (0.37) | SIGMAR1 | |
| SCHEMBL27648212 | 0.81 | MEN1 (0.38) | MEN1HTR2AHTR2CSIGMAR1KDM1A | |
| SCHEMBL27416395 | 0.80 | MEN1 (0.39) | MEN1HTR2AHTR2CSIGMAR1PNMT | |
| Hydrochloric Acid SCHEMBL27675000 | 0.79 | ALDH1A1 (0.39) | SIGMAR1 | |
| SCHEMBL29674239 | 0.75 | HTR2A (0.43) | HTR2AHTR2CPNMTCD44MAOB | |
| SCHEMBL24710630 | 0.75 | MAOB (0.43) | MEN1HTR2AHTR2CPNMTCD44 | |
| SCHEMBL327743 | 0.75 | HTR2A (0.43) | HTR2AHTR2CPNMTCD44MAOB | |
| SCHEMBL17114772 | 0.75 | HTR2A (0.43) | MEN1HTR2AHTR2CPNMTCD44 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176705-A1 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY | WASHINGTON UNIVERSITY (US) | 2009-07-09 | — | — | US | claimed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| US-11505529-B2 | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome | NATIONAL TAIWAN UNIVERSITY (TW) | 2022-11-22 | — | — | US | disclosed |
| CN-104672136-B | 1-substituted phenanthryl-N-alkyl (acyl)-6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline derivative as well as preparation method and purpose thereof | 沈阳药科大学 | 2017-01-25 | — | — | CN | disclosed |
| WO-2016174496-A1 | P-GP RADIOTRACERS FOR IMAGING AS BIOMARKER INVOLVED IN ONSET OF NEURODEGENERATIVE DISEASES | BIOFORDRUG S.R.L. (IT) | 2016-11-03 | — | — | WO | disclosed |
| CN-103664804-B | Pirodomast analogue, preparation method and application thereof | ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-103664804-A | Picotamide analogues as well as preparation method and application thereof | ANHUI UNIVERSITY OF CHINESE MEDICINE | 2014-03-26 | — | — | CN | disclosed |
| US-8575158-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-05 | — | — | US | disclosed |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8143222-B2 | Modular platform for targeted therapeutic delivery | WASHINGTON UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | ANALYTECON S.A. (CH) | 2007-06-07 | — | — | US | disclosed |
| US-20060040919-A1 | Bronchorelaxing compounds | RESPIRATORIUS AB (SE) | 2006-02-23 | — | — | US | disclosed |
| EP-1603884-A2 | PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE, AND NAPHTHALENE UROTENSIN-II RECEPTOR ANTAGONISTS. | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050165004-A1 | Bronchorelaxing compounds | RESPIRATORIUS AB (SE) | 2005-07-28 | — | — | US | disclosed |
| WO-2004078114-A2 | PYRIDINE, PYRIMIDINE, QUINOLINE, QUINAZOLINE, AND NAPHTHALENE UROTENSIN-II RECEPTOR ANTAGONISTS. | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-1997023484-A1 | NEW COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1997-07-03 | — | — | WO | disclosed |
| EP-0382628-B1 | Aminoalkoxylphenyl derivatives, process for their preparation and compositions containing them | SANOFI ELF (FR) | 1994-05-04 | — | — | EP | disclosed |
| EP-0351255-B1 | Derivatives of 2-[(4-piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy | SYNTHELABO (FR) | 1993-10-13 | — | — | EP | disclosed |
| EP-0382628-A1 | Aminoalkoxylphenyl derivatives, process for their preparation and compositions containing them | ELF SANOFI (FR) | 1990-08-16 | — | — | EP | disclosed |
| EP-0351255-A2 | Derivatives of 2-[(4-piperidinyl)methyl]-1,2,3,4-tetrahydroisoquinoline, their preparation and their use in therapy | SYNTHELABO (FR) | 1990-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505529-B2 | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome | HTR7, GPR27, HTR5A | MEN1 4859/4885HTR2A 23/4885HTR2C 9/4885 |
| US-20050165004-A1 | Bronchorelaxing compounds | GPR6, CHRM3, NR1H3 | MEN1 1409/4885HTR2A 585/4885HTR2C 944/4885 |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | MEN1 3717/4885HTR2A 216/4885HTR2C 311/4885 |
| US-20060040919-A1 | Bronchorelaxing compounds | CHRM3, GPR3, CHRM2 | MEN1 2210/4885HTR2A 1155/4885HTR2C 1668/4885 |
| US-20090176705-A1 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY | SIGMAR1, TMEM97, CCAR2 | MEN1 4666/4885HTR2A 59/4885HTR2C 237/4885 |
| US-20070129399-A1 | Tetrahydroisoquinoline-and tetrahydrobenzazepine derivatives as igf-1r inhibitors | IGF1R, INSR, GPR119 | MEN1 1041/4885HTR2A 146/4885HTR2C 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.